Business Wire

DE-CSC

9.10.2019 14:02:11 CEST | Business Wire | Press release

Share
CSC Introduces New Domain Name Security Intelligence API at the Cyber Defense Summit 2019 Hosted by FireEye

CSC announces a new domain name security intelligence API that can now bring together the power of CSC’s domain name security intelligence with other cloud-based security operations platforms. Debuting today at the FireEye Cyber Defense Summit 2019, this new solution will help the world's leading security experts, government leaders, and executives from various industries address important challenges in today’s cyber threat landscape, including the vulnerability of digital assets like domains, domain name systems (DNS), and digital certificates outside the firewall, noted by both companies as serious security blind spots.

Cyber threats such as domain name and DNS hijacking events enable criminals to redirect web traffic, email, apps, and other connections to services that rely on the hijacked domain name. The exploitation of weaknesses in DNS infrastructure is caused by a lack of controls, processes, and policies with most organizations. For clients leveraging a security operations platform or a SIEM, it’s now possible to display all your security intelligence in one place, adding security controls for domains, DNS, and digital certificates. This insight can help organizations mitigate the disruption of business continuity, leading to financial repercussions, loss of consumer trust, and sensitive data leaks. This is the first time any organization is able to integrate security controls for digital assets outside the firewall into their security operations platform including a SIEM.

“Customers today have vendor fatigue and are overwhelmed by managing multiple, disparate security solutions. With the CSC API accessible, our mutual customers will be able to monitor a suite of security events that occur outside their company’s firewall when integrated with the FireEye Helix Security Platform,” says Sean Morton, vice president of Customer Experience at FireEye. “Detecting risks such as DNS and domain name hijacking removes a significant blind spot in a company’s security strategy, providing valuable intelligence and alerts inside our security operations platform, ultimately increasing the efficiency and incident response times dealing with cyber threats.”

“As the world’s leading corporate domain name registrar, CSC is the only company in the unique position to provide visibility into the cyber risks associated with your business-critical digital assets outside the firewall—domains, DNS, and digital certificates. Coupled with other security operations platforms like FireEye Helix, our joint customers have access to a next generation security platform,” says Mark Calandra, senior vice president, CSC Digital Brand Services. “In response to the risk of DNS hijacking and other cyber crime noted in the Department of Homeland Security’s emergency directive and the UK National Cyber Security Centre’s security advisory , CSC’s advanced proprietary algorithms are designed to expose these blind spots that are a critical component for enhancing the security posture of any company with an online presence.”

The Cyber Defense Summit is being hosted by FireEye, and the conference takes place October 9-10, 2019, in Washington, D.C. CSC representatives will be in the exhibition hall to discuss CSC’s new Domain Name Security Intelligence API and its integration with FireEye Helix. We will also be discussing our recent Cyber Security Report highlighting the domain name security posture of global government defense contractors.

About CSC

CSC supports companies that are making significant investments in their security posture by exposing blind spots that exist within fundamental internet assets such as domain names, DNS, and digital certificates. By leveraging our proprietary security solutions, CSC secures companies from cyber threats to their digital assets, helping them avoid devastating revenue loss, brand reputation damage, or significant financial penalties as a result of policies like GDPR. Along with internet assets, CSC protects online brands that are being exploited via counterfeit websites, fraud, and IP violations, and helps monitor and mitigate this, providing enforcement and advisory services to protect many of the world’s largest brands. Learn more at cscdigitalbrand.services .

About FireEye, Inc.

FireEye is the intelligence-led security company. Working as a seamless, scalable extension of customer security operations, FireEye offers a single platform that blends innovative security technologies, nation-state grade threat intelligence, and world-renowned Mandiant® consulting. With this approach, FireEye eliminates the complexity and burden of cyber security for organizations struggling to prepare for, prevent, and respond to cyber-attacks. FireEye has over 8,200 customers across 103 countries, including more than 50 percent of the Forbes Global 2000.

Link:

ClickThru

Social Media:

https://www.facebook.com/CSCSince1899/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Backed by Investments Exceeding $1 Billion, PCI Pharma Services Announces Major Expansion of US Sterile Fill-Finish and Drug-Device Delivery Combination Capabilities27.4.2026 16:00:00 CEST | Press release

As pharma manufacturers prioritize US supply chain resilience, highlights include high-speed isolator filling lines for prefilled syringes, cartridges and vials, and drug-device combination assembly and packaging. PCI Pharma Services (“PCI”) – a world-leading integrated global contract development and manufacturing organization (CDMO) focused on innovative biologic and small molecule therapies – announced a series of major infrastructure investments that substantially deepen its sterile fill-finish and advanced drug delivery capabilities. As pharma manufacturers and their development partners increasingly prioritize US supply chain resilience, PCI’s latest investments come as part of a broader commitment exceeding $1 billion across the CDMO’s US and European operations, reinforcing its ability to provide seamless support for drug product development and manufacturing, clinical trial supply and drug-device combination assembly from clinical stages through commercial launch – all underpi

Pure Lithium Appoints Renowned Battery Expert Dr. Yuan Gao to Board of Directors27.4.2026 15:53:00 CEST | Press release

Pure Lithium Corporation, a vertically integrated lithium metal battery technology company, is pleased to announce that world-renowned inventor and battery expert Dr. Yuan Gao has joined the company’s Board of Directors. Dr. Gao has been an invaluable member of Pure Lithium’s Scientific Advisory Board since October of 2023. "We are thrilled to have Dr. Gao join our board as we focus on rapidly scaling our technology in the most capital efficient manner possible,” said Pure Lithium Founder, Chairman and CEO Emilie Bodoin. “Dr. Gao is a brilliant scientist who also has deep commercial expertise, a rare combination. He is also unique in the industry because his experience spans the entire battery materials value chain, including all of Pure Lithium’s verticals. His insights over the years have been critical in advancing our technology, and his experience as a director of public companies will strengthen our board.” Dr. Gao commented: “I am thrilled to join the board of Pure Lithium Corpor

Taiho Oncology, Taiho Pharmaceutical and Araris Biotech AG Advance ADC ARC-02 into Phase 1 Clinical Development27.4.2026 15:00:00 CEST | Press release

Phase 1 dose-escalation trial represents the first clinical trial of a product developed using the AraLinQ™ ADC technology and marks Taiho’s expansion into the clinical development of ADCs for oncology Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Araris Biotech AG (“Araris”) today announced that the U.S. Food and Drug Administration (FDA) has completed its Investigational New Drug (IND) review period for ARC-02, an antibody-drug conjugate (ADC) being developed for the treatment of non-Hodgkin lymphoma, enabling Taiho Oncology to initiate a Phase 1 dose-escalation clinical trial of ARC-02. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427127507/en/ Taiho Pharmaceutical acquired Araris Biotech in March 2025, expanding Taiho group’s capabilities in biologics and ADC research and development. Araris is a spin-off of the Paul Scherrer Institute and ETH in Switzerland focused on the development of antibody-drug co

Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 202627.4.2026 15:00:00 CEST | Press release

Premier global event to highlight how organizations are bringing data to life to power everything from AI to BI Boomi, the data activation company, today announced Boomi World 2026, its premier annual user conference, taking place May 11 - 14, 2026 in Chicago, IL. The event will bring together customers, partners, and industry leaders from around the world to explore how data activation is transforming the enterprise and accelerating the path to AI-driven outcomes. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427600340/en/ Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 2026 Boomi World 2026 will spotlight data activation — bringing data to life to power AI, analytics, and intelligent automation. Attendees will gain firsthand insights into how the Boomi Enterprise Platform enables businesses to unify data, streamline operations, and innovate faster in an increasingly agentic world.

Axinn Appoints Rachael Philbin as Chief Innovation Officer27.4.2026 15:00:00 CEST | Press release

Appointment Reflects Firm's Vision for the Future of Legal Practice Axinn, Veltrop & Harkrider LLP today announced the appointment of Rachael Philbin as Chief Innovation Officer, reinforcing the firm’s continued investment in advanced solutions and technology for legal services delivery. Philbin joins from Proskauer Rose LLP, where she served as Innovation & Transformation Officer. Based in Axinn's New York office, she will lead the firm’s AI and legal technology initiatives as well as knowledge management efforts, accelerating adoption and integration across its antitrust, intellectual property, and litigation practices. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427277725/en/ Rachael Philbin joins Axinn, Veltrop & Harkrider LLP as Chief Innovation Officer. “As Axinn continues to grow, we are making deliberate investments in the capabilities that enable our lawyers to deliver service and results at the highest level

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye